Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/2B30 stock hub

FRA/2B30 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/2B30is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

957.8M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/2B30FRA/2B30

—

Loading chart…

In the news

Latest news · FRA/2B30

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E30.3

P25 n/aP50 n/aP75 n/a

Trailing P/E92

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC8.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/2B30 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

170

Groups with data

Currency

USD

Showing 170 of 170 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	435
Employees Change	17%
Employees Change Percent	4.51
Enterprise value	EUR 1.1B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 957.8M
Price	EUR 5.33
Price currency	EUR
Rev Per Employee	627,751.74x
Sic	2834
Symbol	fra/2B30
Website	https://www.xerispharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.09%
EV Earnings	103.94x
EV/EBIT	35.49x
EV/EBITDA	22.73x
EV/FCF	26.27x
EV/Sales	4.05x
FCF yield	4.3%
Forward P/E	30.33x
P/B ratio	84.88x
P/E ratio	91.97x
P/S ratio	3.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.4%
EBITDA Margin	15.27%
FCF margin	15.09%
Gross margin	85.89%
Gross Profit	EUR 234.6M
Gross Profit Growth	47.81%
Gross Profit Growth Q	41.18%
Gross Profit Growth3 Y	39.47%
Gross Profit Growth5 Y	72.95%
Net Income	EUR 10.4M
Pretax Margin	3.81%
Profit Margin	3.81%
Profit Per Employee	EUR 23,941
ROA	6.34
Roa5y	-10.92
ROCE	13.13
ROIC	8.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	42.98%
Cagr3y	37.29%
Revenue Growth	41.48x
Revenue Growth Q	38.27x
Revenue Growth3 Y	37.4x
Revenue Growth5 Y	63.63x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.89
Assets	EUR 340M
Cash	EUR 96.9M
Current Assets	EUR 213.4M
Current Liabilities	EUR 100.6M
Debt	EUR 224.2M
Debt EBITDA	EUR 4.61
Debt Equity	EUR 19.87
Debt FCF	EUR 5.44
Equity	EUR 11.3M
Interest Coverage	1.25
Liabilities	EUR 328.7M
Long Term Assets	EUR 126.6M
Long Term Liabilities	EUR 228.1M
Net Cash	EUR -127.3M
Net Cash By Market Cap	EUR -13.29
Net Debt EBITDA	EUR 3.05
Net Debt Equity	EUR 11.28
Net Debt FCF	EUR 3.09
Tangible Book Value	EUR -82.6M
Tangible Book Value Per Share	EUR -0.48

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.12
Inventory Turnover	0.7
Net Working Capital	EUR 23.9M
Quick ratio	1.42
Working Capital	EUR 115.4M
Working Capital Turnover	EUR 2.71

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-19.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	42.95%
200-day SMA	5.99
3Y total return	158.84%
50-day SMA	5.03
50-day SMA vs 200-day SMA	50under200
All Time High	8.48
All Time High Change	-37.09%
All Time High Date	2025-11-05
All Time Low	0.97
All Time Low Change	452.25%
All Time Low Date	2023-01-06
ATR	0.13
Ch YTD	-13.86
High	5.33
High52	8.48
High52 Date	2025-11-05
High52ch	-37.09%
Low	5.33
Low52	3.72
Low52 Date	2025-06-13
Low52ch	43.49%
Ma50ch	5.92%
Price vs 200-day SMA	-11%
RSI	62.25
RSI Monthly	56.78
RSI Weekly	50.25
Sharpe ratio	0.57x
Sortino ratio	1.01
Total Return	-19.55%
Tr YTD	-13.86
Tr1m	3.49%
Tr1w	1.52%
Tr3m	-7.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 31.1M
Operating margin	11.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	163,824,629%
Shares Insiders	5.1%
Shares Institutions	59.64%
Shares Qo Q	-1.36%
Shares Yo Y	19.55%
Short Ratio	8.37

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 22.1M
Average Volume	8.5x
Bv Per Share	0.07
CAPEX	EUR -874,238
Ch1m	3.49
Ch1w	1.52
Ch1y	42.95
Ch3m	-7.51
Ch3y	158.8
Ch6m	-19.09
Change	2.22%
Change From Open	0
Close	5.22
Days Gap	2.22
Depreciation Amortization	10,326,481.2
Earnings Date	2026-05-07
EBIT	EUR 31.1M
EBITDA	EUR 41.7M
EPS	EUR 0.06
F Score	7
FCF	EUR 41.2M
FCF EV Yield	3.81x
Financing CF	4,934,070
Fiscal Year End	December
Founded	2,005
Goodwill	19,383,563.4
Graham Number	0.28626
Graham Upside	-94.63
Investing CF	-874,238
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Ma150	5.99
Ma150ch	-10.94%
Ma20	5.16
Ma20ch	3.43%
Net CF	46,147,298
Open	5.33
P FCF Ratio	23.24
P OCF Ratio	22.76
Ppne	22,879,710.7
Price Date	2026-05-07
Price EBITDA	EUR 22.97
Relative Volume	20x
Revenue	273,072,007x
SBC By Revenue	7.01x
Share Based Comp	19,135,240
Tr6m	-19.09%
Z Score	0.79

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/2B30 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/2B30 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/2B30?

Insider, institutional, and short-interest positioning.

Institutional ownership

+59.6%

Share of float held by funds and institutions

Insider ownership

+5.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/2B30 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

62.2

Neutral momentum band

Price vs 200-day MA

-11.0%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.57

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/2B30

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/2B30 stock rating?

fra/2B30 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/2B30 analysis?

The full report lives at /stocks/fra/2B30/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/2B30?

The latest report frames fra/2B30 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/2B30 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.